Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza A and B virus infections in February 2018 in Japan. Because of the need to monitor influenza viruses for reduced susceptibility to this drug, we used two cell-based screening systems – a con...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Microbiol
Egile Nagusiak: Takashita, Emi, Morita, Hiroko, Ogawa, Rie, Nakamura, Kazuya, Fujisaki, Seiichiro, Shirakura, Masayuki, Kuwahara, Tomoko, Kishida, Noriko, Watanabe, Shinji, Odagiri, Takato
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2018
Gaiak:
Microbiology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291754/
https://ncbi.nlm.nih.gov/pubmed/30574137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmicb.2018.03026
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak